Kyverna Therapeutics (KYTX) Profit After Tax (2023 - 2026)
Kyverna Therapeutics' (KYTX) quarterly Profit After Tax came in at -$39.9 million in Q1 2026, up 10.77% YoY from -$36.0 million in Q1 2025, and down 5.61% on a QoQ basis from -$37.8 million in Q4 2025.
Kyverna Therapeutics (KYTX) Profit After Tax (2023 - 2026) Analysis & Trends
Kyverna Therapeutics (KYTX) has 4 years of Profit After Tax data on file, last reported at -$39.9 million in Q1 2026.
- Quarterly Profit After Tax rose 10.77% year-over-year to -$39.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$156.6 million (down 7.62% YoY) and the FY2025 annual result came in at -$161.3 million, down 26.51% from the prior year.
- Profit After Tax declined to -$39.9 million in Q1 2026, from -$37.8 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of $5000.0 in Q3 2023 to a low of -$60.4 million in Q4 2023.
- A 4-year average of -$31.8 million and a median of -$36.8 million in 2025 frame the typical range for Profit After Tax.
- The widest YoY moves for Profit After Tax: up 37.64% in 2024, down 686140.0% in 2024.
- Tracing KYTX's Profit After Tax over 4 years: stood at -$60.4 million in 2023, then jumped by 37.64% to -$37.7 million in 2024, then dropped by 0.37% to -$37.8 million in 2025, then slipped by 5.61% to -$39.9 million in 2026.
- The last three Profit After Tax figures came in at -$39.9 million (Q1 2026), -$37.8 million (Q4 2025), and -$36.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Kyverna Therapeutics | 505.26 Mn | 505.26 Mn | - | -38.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -38.37 Mn |
| Mar 31, 2026 | -39.92 Mn |
| Dec 31, 2025 | -37.80 Mn |
| Sep 30, 2025 | -36.79 Mn |
| Jun 30, 2025 | -42.08 Mn |
| Mar 31, 2025 | -44.74 Mn |
| Dec 31, 2024 | -37.66 Mn |
| Sep 30, 2024 | -34.30 Mn |
| Jun 30, 2024 | -28.80 Mn |
| Mar 31, 2024 | -26.69 Mn |
| Dec 31, 2023 | -60.40 Mn |
| Sep 30, 2023 | 5,000.00 |
| Jun 30, 2023 | -13.09 Mn |
| Mar 31, 2023 | -11.14 Mn |